Arzerra Interactions
There are 160 drugs known to interact with Arzerra (ofatumumab), along with 5 disease interactions. Of the total drug interactions, 49 are major, and 111 are moderate.
- View all 160 medications that may interact with Arzerra
- View Arzerra disease interactions (5)
Most frequently checked interactions
View interaction reports for Arzerra (ofatumumab) and the medicines listed below.
- Abilify MyCite (aripiprazole)
- acetaminophen
- acetaminophen / hydrocodone
- Actemra (tocilizumab)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Adempas (riociguat)
- Adriamycin (doxorubicin)
- Advair Diskus (fluticasone / salmeterol)
- Afinitor (everolimus)
- Afinitor Disperz (everolimus)
- Afstyla (antihemophilic factor)
- Aggrenox (aspirin / dipyridamole)
- Akynzeo (netupitant / palonosetron)
- Aldurazyme (laronidase)
- Alimta (pemetrexed)
- Alprazolam Intensol (alprazolam)
- amantadine
- Farydak (panobinostat)
- Gilenya (fingolimod)
- Gleevec (imatinib)
- Hyzaar (hydrochlorothiazide / losartan)
- Jakafi (ruxolitinib)
- Januvia (sitagliptin)
- Lamictal (lamotrigine)
- Lyrica (pregabalin)
- Mekinist (trametinib)
- Nexium (esomeprazole)
- Promacta (eltrombopag)
- Votrient (pazopanib)
Arzerra disease interactions
There are 5 disease interactions with Arzerra (ofatumumab) which include:
- Anti-CD20 antibodies – hepatitis B
- Anti-CD20 antibodies – infections
- tumor lysis syndrome
- cardiopulmonary disease
- cytopenias
More about Arzerra (ofatumumab)
- Arzerra consumer information
- Compare alternatives
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: CD20 monoclonal antibodies
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.